You Won't Believe What This Groundbreaking Breast Cancer Vaccine Could Mean for Millions at Stony Brook!

At just 35, Christine Amitrano received a breast cancer diagnosis that would change her life forever. Now 41, she reflects on her journey with gratitude, particularly that her cancer was discovered early. After two years of rigorous treatment, Amitrano has enrolled in a clinical trial for an experimental vaccine aimed at reducing the risk of her cancer recurring. "Research is the most important thing that people can volunteer for," she stated during an interview at Stony Brook Medicine’s Cancer Center. Though she is unaware if she’s receiving the vaccine or a placebo, she recognizes that the treatments she benefited from were made possible through those who participated in such trials before her.

Stony Brook Cancer Center is one of 160 sites worldwide involved in the FLAMINGO-01 Phase III clinical trial, conducted by Greenwich LifeSciences, a biopharmaceutical company based in Texas. This trial specifically targets individuals diagnosed with HER2-positive breast cancer, a subtype known for its aggressive nature. Participants are administered a series of six injections over six months, followed by five booster injections spaced six months apart.

The focus of the trial is to prevent cancer from returning and escalating into a metastatic disease, wherein the cancer spreads beyond the breast tissue into other organs. Dr. Jules Cohen, a medical oncologist at the Stony Brook Cancer Center who treats Amitrano, emphasizes the importance of addressing this issue. "In women who do develop metastatic breast cancer, there have been successes in keeping them alive as long as possible and with the best quality of life. However, once the disease spreads to the liver, lungs, bones, or even the brain, it becomes terminal," he explained. "We’re looking for ways to try to reduce the risk of metastatic recurrence in these early-stage patients."

Interestingly, most women do not get their baseline mammogram until the age of 40, unless they are identified as high-risk due to family history or other factors. Amitrano’s mother, a nurse who was adopted and thus had no knowledge of her biological family's medical history, encouraged her daughter to get screened early. This proactive approach led to the discovery of a lump in Amitrano's left breast and a mass in her right breast, which, while benign, was a shocking diagnosis of stage 2 cancer in the other. "We were shocked," she recalled. "I really didn’t think anything was wrong."

If she had waited longer for the screening, doctors explained, the cancer could have advanced significantly, making treatment more challenging. Following her diagnosis, Amitrano underwent chemotherapy, surgery, and radiation. Although there are currently no signs of cancer, she remains vigilant, taking long-term medication and attending regular screenings.

The experience dramatically shifted her career trajectory; she transitioned from being a physical education teacher to an MRI X-ray technician. "When I was going through radiation therapy, I started to get interested in it," Amitrano said. "It is so important to get diagnosed early, and I like to be in a field that helps people."

Stony Brook is actively seeking participants diagnosed with HER2-positive breast cancer for the ongoing clinical study, and Amitrano encourages others in her situation to join. "All the treatments that we have now were established through the participation of patients all around the country and all around the world in clinical trials," Dr. Cohen reiterated. "Step by step, treatments have gotten better, leading to more patients being cured."

While concerns about health risks often deter some individuals from participating in clinical trials, Cohen points out that safety measures are rigorously enforced. "Participants are constantly monitored. There's a lot of scrutiny on clinical trial participants," he stated. "You come to the Cancer Center more frequently, and you have a whole clinical trials team taking care of you. We're watching everything very closely."

Amitrano’s experience highlights the critical intersection of early detection and innovative research in the fight against breast cancer. With ongoing advancements and clinical trials like the FLAMINGO-01, the hope is that women diagnosed with HER2-positive breast cancer will have more effective options for preventing recurrence and improving their quality of life.